SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size, portable 3D-vector electrocardiogram (VECG) platform that is always with the patient, allowing for the creation of rich data for AI, today announced that the United States Patent and Trademark Office has granted a new patent on HeartBeam’s novel VECG platform.
The latest patent, “Electrocardiogram Patch Devices and Methods” (Patent number 11,793,444) describes methods and systems for remote detection and/or diagnosis of acute myocardial infarction (AMI or heart attack) through handheld and adhesive devices. This is HeartBeam’s third issued US patent on its novel on-demand 12-lead (“12L”) wearable cardiac monitor, strengthening the company’s position in the large global electrocardiogram (“ECG”) patch market which is estimated to reach $4.8B by 2030.
An estimated 6 million ambulatory cardiac monitors are used annually in the US to assess intermittent heart symptoms. One type of ambulatory cardiac monitor is an extended wear patch, generally consisting of a single lead ECG limiting detection of cardiac conditions, worn continually for up to 14 days.
HeartBeam’s groundbreaking on-demand 12L patch consists of a small, continuous single-lead ECG that can be instantly converted to a 12L ECG to record symptoms as they occur. HeartBeam believes that this can provide significant advantages over existing devices, with the ability to record higher resolution signals and to detect conditions that single lead devices cannot, including ischemia and heart attacks.
HeartBeam now has 11 issued US patents and 4 issued international patents, along with 18 pending international applications. These patents cover the core inventions in HeartBeam’s VECG technology, as well as the specific applications across HeartBeam’s product portfolio, including patient carried devices (HeartBeam AIMIGo™), continuous monitors (LIVMOR), extended wear patches, and watch-based 12L ECGs.
“This patent represents an integral part of the company’s strategy to ensure HeartBeam’s disruptive technology is well protected,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam. “We believe our 12-lead ECG technology has the potential to become the standard of care and are actively pursuing options to bring the 12-lead extended wear patch to market.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
